Recent studies reveal success in treating spinal cord trauma with early, high-dose methylprednisolone. As in spinal cord research, failure to find therapeutic effects with steroids in studies of acute stroke treatment may reflect institution of treatment too late and at too low dosage. We presently test the efficacy of stroke treatment with methylprednisolone administered early and at high doses using a cat temporary middle cerebral artery occlusion model.
A lthough it was earlier believed that corticosteroids / \ might be useful for stroke treatment, recent J. \ . opinion holds they are ineffective in treating either the cytotoxic or the vasogenic edemas of ischemia. 1 However, several clinical and animal experimental studies have described definite therapeutic benefits of methylprednisolone (MP) treatment in protecting the brain from injury caused by ischemia. 2 " 4 Braughler and Lainer 4 found that MP, at very high doses, protects the Mongolian gerbil brain from injury from cerebral ischemia. However, MP, when used at still higher or at lower doses in the same model, proved to be ineffectual. A similar dose-dependent, therapeutic effect for MP is described to treat spinal cord trauma. 5 These provocative findings prompted the retesting of MP for its efficacy in treating human spinal cord injury at high doses in a multicenter clinical trial. This reexamination proved MP effective in reducing the neurological sequelae of spinal cord injury in humans. 6 If this MP schedule is effective in treating spinal cord trauma, might it not also be effective in treating ischemic strokes? In studies with gerbils, Braughler and Lainer 4 demonstrated MP to be effective only when administered before cerebral ischemia was produced by neck vessel occlusion. The lack of effectiveness when administered after vessel occlusion was due possibly to limited drug access to the ischemic brain caused by marked hypoperfusion during the reperfusion phase. A stroke model with a well-developed ischemic penumbra (as displayed by the cat with middle cerebral artery [MCA] occlusion and also by humans subject to major ischemic strokes) should provide drug access to the brain during ischemia. With this access, MP treatment may be effective even though the drug is administered only after occlusion has occurred.
The presence of an ischemic penumbra in a model in which a short duration of ischemia produces no neuronal injury, but in which damage progresses as the ischemia is prolonged, is important for studies of pharmacologic stroke treatment because such a model provides the possibility for a clinically relevant amelioration of outcome. 79 MCA occlusion in cats provides a substantial ischemic penumbra in the affected hemisphere; decreasing percentages of cats remain brain-intact after 4 and 8 hours of temporary and after permanent occlusion, ie, 50%, 30%, and <10%, respectively. 10 The present study uses a hyperglycemic, 4-hour MCA occlusion model in cats 11 to study early, high-dose MP treatment effects corresponding in timing and dose to MP used in spinal cord injury in humans. 6 In this model, cats without treatment develop infarcts the mean size of which encompasses about 50% of the MCA territory. This infarct size readily permits drug effects to alter outcome in either direction. Indeed, some authors have suggested that use of steroids for stroke treatment may be deleterious. 12
Methods
We tested the efficacy of high-dose MP in treating stroke using a blinded, random study design that included 12 MPtreated animals and 12 vehicle controls. The experimental model involved a 4-hour temporary MCA occlusion in cats in which hyperglycemia was maintained during and for 6 hours after MCA occlusion. Maintaining hyperglycemia in the animals increases their vulnerability to injury from reversible focal ischemia." The details of the methods used in the present study follow those already described. 11 ' 13 
MP Treatment
We structured the MP treatment regimen used in the present study after that described for treatment of acute spinal cord trauma in humans. 6 Thus, we infused MP 30 mg/kg body weight IV over 15 minutes starting 30 minutes after MCA occlusion. We followed this initial high dose with a maintenance dose of 5.4 mg*kg~'*h~' starting 90 minutes after occlusion and lasting for the next 23 hours. We administered the same volumes of vehicle to the control animals as we gave of the drug to the experimental animals. All members of the investigative team carrying out the experimental procedures were blinded regarding the composition of the solutions administered; the code was broken only after all end points had been assessed.
Anesthesia and Physiological Monitoring
The conditioned cats used in the present study were deprived of food for 48 hours (but allowed free access to water) to provide stable serum glucose concentrations during the study period. On the day of the procedure, we anesthetized the cats with pentobarbital 35 mg/kg IV. Thereafter, we provided 2 mg • kg"' • h" 1 pentobarbital supplements during the period of MCA occlusion and throughout the ensuing 8 hours of postoperative monitoring. We catheterized the right femoral artery and vein to monitor the mean arterial blood pressure (MABP) and heart rate, to sample the arterial blood for acid-base and respiratory gas determinations, to infuse 10% glucose solutions intravenously, to administer drugs or vehicle, and to transfuse donor blood periodically to compensate for blood loss caused by sampling or surgery. We started 10% glucose infusions intravenously an estimated 1 hour before MCA occlusion and adjusted the infusion rate to maintain the serum glucose concentration at 20 to 22 mmol/L during and for 6 hours after occlusion. We maintained the cats' body temperature at 38.5±0.5°C by applying external heat as needed. We also monitored brain temperature but did not use the brain temperature to regulate body temperature.
Surgical Procedures
We exposed the right cranium and inserted cerebral blood flow (CBF) and brain temperature probes through two diminutive cranial openings created with a fine caliber dental burr. We positioned the flow and temperature probes in the anterior and posterior perisylvian cortex, respectively (sites located near the center of the ischemic MCA territory). Using a transorbital approach, we exposed the posterior roof of the orbit and created a small bone opening at the base of the brain using a larger dental burr. After identifying the MCA as it passes lateral to the olfactory tract, we applied a miniature Yasargil aneurysm clip 6 to 7 mm lateral to the midline. We then removed the clip 4 hours later to restore blood flow through the previously ischemic MCA territory.
CBF Measurement
We determined CBF using the hydrogen clearance technique as described by Pasztor et al. 14 For that purpose, we implanted a fine, Teflon-insulated platinum wire electrode (90% platinum, 10% iridium, Medwire Corp, Mt Vernon, NY) into the anterior perisylvian cortex close to the center of the MCA supply territory. After fixing this electrode in place using dental cement, we attached a silver reference electrode to the temporal muscle. For individual CBF measurements, the animals breathed spontaneously 100% hydrogen gas for 5 seconds through a face mask.
The CBFs were calculated from the hydrogen washout curves using the Fick principle. We measured the CBF before MCA occlusion and hourly thereafter for 8 hours. We also monitored multiple cardiovascular and blood compositional parameters and brain temperature throughout the same period. We estimated the ages of the animals using the 5-point scoring system described by Tomita et al. 15 
Animal Exclusion
Animals were excluded from the study if they sustained > 10 mL blood loss during surgery; for persistent bleeding into the subarachnoid space; because of uncertainty of aneurysm clip placement during surgery; for intercurrent viral illnesses (pneumonias) during animal survival; for deviant physiological values including MABP reductions <85 mm Hg; for a body temperature <37.5°C or >40.0°C; for a Pao 2 <80 mm Hg; for a Paco 2 >50 mm Hg; or for a blood pH <7. 10 . Those cats that died from hemispheric edema and brain stem compression during the first days after MCA occlusion were included in the study because such brain edema development and acute animal death represents one of the expected outcomes of MCA occlusion.
Postoperative Care and Neurological Evaluation
All cats received routine postoperative care until they either (1) died within the first 2 days of hemispheric edema and brain stem compression or (2) recovered from anesthesia and their condition stabilized. We maintained surviving cats for 4 days in a standard animal-care setting. During the period of postoperative maintenance, they received intramuscular analgesics (nalbuphine hydrochloride 1 mg/kg TID). We evaluated each animal's neurological status daily following the procedure. After the cats survived for 4 days, they were deeply anesthetized with pentobarbital 60 mg/kg IP. After they reached deep anesthesia, we perfused their bodies with 10% buffered formalin. We removed their brains and the brains of animals that died spontaneously from hemispheric edema and fixed or post-fixed them for 2 weeks in buffered formalin.
Brain Pathological Examination
We examined the formalin-fixed brains grossly for evidence of edema, tissue herniation, and areas of cortical softening or discoloration. Furthermore, we assessed the extent of brain herniation (a measure of brain edema in fixed brains) semiquantitatively using the sums of 0 to 4+ scores depicting the degrees of herniation at five locations: posterior cingulate cortex, herniation past the tentorium ipsilaterally (1) and contralaterally (2) to MCA occlusion, (3) orbitofrontal cortex herniation through the parachiasmatic bone opening used for MCA occlusion, (4) herniation of the vermis through the foramen magnum, and (5) shift across the midline of the ischemic hemispheric tissue. We then sliced the brains coronally into six standard sections and embedded them in paraffin. Whole-mount sections were stained with hematoxylin and eosin and examined microscopically.
We estimated infarct sizes morphometrically from the microscopic brain sections in all cats killed electively after 4 days of survival. Areas of tissue injury or infarction and total ipsilateral cerebral hemispheric areas were measured on each of the six standard brain sections using computer-assisted morphometry (BioQuant, Nashville, Tenn). The sura of the total brain parenchymal areas in the affected hemisphere was set as 100%, and the sum of the infarcted areas was expressed as a percentage of the whole hemisphere. Because the area measurements are taken from standard brain sections encompassing the entire hemisphere, the area measurements are proportionate to volume. By expressing the infarct as percentage of hemispheric volume, the influence of the variable tissue shrinkage that develops during dehydration and paraffin embedding is minimized. Finally, we expressed the volume of an infarct as a percentage of the MCA territory assuming this to be one half of the total hemispheric volume (based on unpublished carbon black injection studies).
We defined two distinct categories of brain pathological outcome in the present study: (1) instances in which the cats died in the first 2 days after MCA occlusion from marked edema of the ischemic MCA territory causing herniation of brain tissue and brain stem compression, and (2) instances in which the cats survived and were killed electively 4 days later to measure infarct size. We also used a third measure of outcome in which the animals of the first two outcomes were combined, including those that died early from hemispheric edema and those that survived with microscopically welldefined infarcts. In this third measure of outcome, cats that died early from hemispheric edema were assigned maximal infarct volume values of 100% since all such animals showed both the gross and the microscopic findings of edema and acute tissue infarction (pale-staining vacuolated brain with acute neuronal changes) that affected the entire estimated MCA territory.
Statistical Analyses
We compared the two animal groups with respect to five different physiological and CBF values measured at six separate time points using ANOVA. We used median infarct volumes in those instances when we made comparisons between groups that also included cats that died early from hemispheric edema. We used median values in these comparisons because median values are not affected by the values of animals that died acutely because (1) the percentage of tissue infarcted in such animals likely is higher than that in the surviving animals and (2) the percentage of animals that died acutely from hemispheric edema is less than 50% of each group. For comparisons of infarct size, we used the square root transformation to approximate the normality condition and performed the one-way ANOVA procedure with the transformed and nontransformed values both for the survivor and combined fatal and survivor groups.
Results
The MP-treated and the untreated animal groups were closely comparable regarding the values of their cardiovascular and blood compositional parameters, their brain and core temperatures, and their estimated ages as can be seen from the Table. Only one group comparison was significant: The MP-treated group at 8 hours after MCA occlusion showed a significantly higher serum glucose concentration compared with the untreated controls (glucocorticosteroid effect). Because elevated serum glucose concentration adversely affects the brain's pathological response to focal ischemia, 11 the smaller infarct sizes in MP-treated surviving animals occurred despite, rather than because of, this difference in glycemia.
The rates with which the cats of the two comparison groups died in the first 2 days from hemispheric edema and brain stem compression and the infarct sizes of the surviving animals of the two groups are presented in Fig  1. The 12 MP-treated cats showed a mortality rate of 25% and an infarct size in the 9 surviving animals of 2.4±0.7% (mean±SEM) of the MCA territory. The 12 animals that served as vehicle controls displayed a 33% mortality rate, whereas the 8 surviving animals in this group showed an infarct size of 15.6±6.2%. This difference in infarct size was statistically significant (P<.05, one-way ANOVA with square root transformation; P=.O2, one-way ANOVA without transformation). The median infarct size for the combined fatal and survivor groups was 3.8% compared with 30.2% of the ischemic territory in MP-treated and control groups, respectively (P>.10). The herniation scores of the animals that died acutely were similar in the MP-treated and the untreated control groups, respectively: n=3,12.7±4.2 versus n=4, 11.0±2.6 (mean±SD).
The MP-treated cats experienced significantly higher CBFs during ischemia than did the vehicle control animals, whereas the CBF rates for the two groups during reperfusion were similar (Fig 2) . Thus, the treated and the control cats showed average reductions in CBF during ischemia of 58.0±4.7% and 73.8±3.6%, respectively (mean±SEM; 32 and 33 measurements, P<.005). As in the two groups as a whole, the subgroup of 3 treated cats that died acutely from hemispheric edema showed less marked reduction in CBF during ischemia (69±2.8% [8 measurements]) than did the 4 control animals that similarly died acutely (96±2.5% [9 measurements]), P<.05.
The MP-treated cats that died from hemispheric edema survived longer after MCA occlusion than did the vehicle controls that similarly died acutely (7 to 25 hours versus 4.25 to 10 hours, respectively). The MPtreated animals also manifested an average ischemic and early reperfusion brain temperature that was significantly higher than in the controls (37.6±0.17°C [53 measurements] versus 37.1±0.4°C [28 measurements]; mean±SEM, P<.05). The difference in ischemic brain temperature in the two groups likely reflects the better preserved ischemic CBF in the MP-treated group. Because even small reductions in brain temperature can reduce ischemic neuronal injury, 16 smaller survivor infarct of the MP group occurred despite, rather than because of, this group's higher brain temperature. Finally, the treated cats showed significantly lower MABP values after clip release (pooled values at 4, 6, and 8 hours) than did the vehicle controls, ie, 125±3 mm Hg (35 measurements) versus 141 ±4 mm Hg (32 measurements), P<. 01.
Discussion
The present study demonstrates that high-dose MP, administered shortly after cerebrovascular occlusion, causes a sixfold reduction in mean infarct size in cats that survive a 4-hour temporary MCA occlusion. This beneficial effect was achieved with a treatment schedule that started with a rapid MP infusion of 30 mg/kg body weight beginning 30 minutes after occlusion, followed by MP infusion of 5.4 mg • kg" 1 1. Bar graph showing morphometric infarct size expressed as a percentage of the middle cerebral artery (MCA) territory (on y axis) of 8 vehicle controls (columns 1 through 8) and 9 methylprednisolone (MP)-treated surviving cats (columns 9 through 17) exposed to 4 hours of MCA occlusion assessed after 4 days of survival. The MP-treated animals' infarct size is significantly smaller than that of the control group (one-way ANOVA after square root transformation). The two groups experienced similar acute mortality rates (MP, 3/12; control, 4/12 animals) from hemispheric edema and brain stem compression.
cord from acute trauma, reducing both the long-term neurological deficits and the extent of posttraumatic tissue destruction in humans and animals. 61718 The present results also comply with the finding that highdose MP treatment of gerbils improves neurological recovery following a 3-hour exposure to bilateral carotid artery occlusion. 4 Furthermore, the present study suggests that MP treatment leads to a significantly better ischemic CBF than that found in the vehicle control animals. This finding agrees with studies that show that high-dose glucocorticosteroids increase blood flow in the spinal cord after experimental trauma by reducing blood vessel resistance 19 -21 and increase CBF in patients with brain tumors. 22 High-dose MP also attenuates the cerebral hypoperfusion that develops after experimental subarachnoid hemorrhage by reducing vasoconstriction. 23 The treated cats of the present study showed higher CBF rates in the ischemic brain territory during ischemia than did the controls, not only in those cats that survived to develop the smaller infarcts but also in the animals that died early of hemispheric edema. MP treatment did not reduce the frequency with which the cats died acutely after temporary MCA occlusion and did not affect the extent of brain herniation exhibited by these animals. Enhancement of blood flow caused by MP treatment during MCA occlusion may partly explain the reduction in tissue infarct size. However, the deaths of the treated animals took place at ischemic CBF levels that untreated animals survived. Thus, the mechanism responsible for infarction and fatal ischemic edema may be distinct in this temporary MCA occlusion model. We did not determine whether MP increased ischemic CBF by dilating cerebral blood vessels. However, such blood vessel dilation may be inferred since MP administration reduced MABP.
The finding that MP treatment fails to reduce mortality from hemispheric edema in the present investigation is surprising because other studies with dexamethasone have described reductions in both focal and global brain edema in cerebral ischemia. 25 -27 Thus, Tosaki et al 27 showed that dexamethasone (2 mg/kg given 5 hours before bilateral carotid occlusion in rats) significantly reduces mortality by suppressing the development of brain edema as measured by changes in brain water and electrolyte contents. Also, in acute head trauma in humans, early high-dose MP treatment (30 mg/kg every 6 hours given twice, then 250 mg every 6 hours given eight times, then tapering over 8 days) markedly reduced the mortality rate. 28 Thus, the pathophysiology of fatal edema from trauma may be more susceptible to be reduced by high-dose MP than is the edema associated with ischemic brain reperfusion.
The present study suggests that protection of the brain from ischemia by high-dose MP is mediated in part by improvements in blood flow. However, other studies suggest that glucocorticosteroids can protect the brain without such changes in CBF. 29 ' 30 Dexamethasone administered at low doses to newborn rats 24 hours (but not 3 hours or immediately) before exposure to 3 hours of hypoxia (8% O 2 ) plus carotid artery occlusion protects the brain. This effect was seen only in newborns; adult treatment failed to show such benefits. However, dexamethasone treatment of the type described profoundly affects the rat pups' glucose metabolism, which may explain its brain-protective effects. Both the rat pup controls and those pretreated immediately or 3 hours before exposure all developed a marked hypoglycemia (to approximately 2 mmol/L blood glucose concentration) by the end of exposure, whereas the pups treated 24 hours before exposure maintained their blood glucose concentrations in the normal-to-slightly hyperglycemic ranges. Since reduction in serum glucose concentration below normal is detrimental during exposure to focal cerebral ischemia regarding exposure to both temporary and permanent cerebral blood vessel occlusion, 3133 the fact that dexamethasone preserves normoglycemia in a model that otherwise becomes markedly hypoglycemic (during hypoxia/ischemia) likely accounts for the reported amelioration of outcome. The basis for this effect being restricted to newborns may reflect the newborn's restricted glucose reserves, which appear to be increased by dexamethasone administration 24 hours earlier. Thus, the beneficial effects that pretreatment with low-dose dexamethasone present appear adequately explained by this drug's effects on glucose metabolism. In contrast, it seems likely that the beneficial effects of high-dose MP in the present model are mediated in part through the role of MP in increasing CBF during ischemia.
Conclusion
The present findings indicate that early treatment with high-dose MP during 4 hours of temporary MCA occlusion in the cat significantly reduces the brain damage produced in animals that survive. This evidence that high-dose MP limits ischemic brain damage in animals suggests that it may act similarly in humans. Thus, the possibility that early high-dose steroid use may be effective for the treatment of stroke in humans needs to be reevaluated. However, the encouragement engendered by the present results is dampened by the fact that high-dose MP treatment fails to reduce early mortality from infarct edema. The challenge remains as to how to control the edema development in brain areas injured by ischemia after reestablishment of blood flow. A solution to this problem would provide the basis to enable stroke patients to fully benefit from reestablished blood flow in areas of focal ischemia. Control of such edema would make it possible to prevent a major portion of acute, stroke-related mortality and to improve stroke outcome as a whole and not only in a subgroup of patients.
